Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 8Phase 1/2 5Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Mouth Neoplasms 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Carcinoma, Squamous Cell 1Carcinoma 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 7Ipilimumab 4pembrolizumab 3Interferon alpha-2 3relatlimab 2Drug Therapy 2Dacarbazine 2sargramostim 1salicylhydroxamic acid 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Vemurafenib 1Triamcinolone Acetonide 1Temozolomide 1Specimen Handling 1Sonazoid 1Ranibizumab 1Propranolol 1Lenalidomide 1Introns 1Immunotherapy 1Imiquimod 1Fatty Acids, Omega-3 1Crizotinib 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Melanoma × Specimen Handling × Clear all
NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡